Ciba-geigy Corporation

University of London

Mitsui Norin Co., Ltd.

Endozyme Limited

School of Pharmacy

Peter William Taylor

Paul Stapleton

Keith Allan Menear

Yukihiko Hara

Wilhelm Kump

William Guy Love

Ian Timothy Matthews

James C Anderson

Catherine Headley

Jane I Lowrie

Jonathan Mark Bryant

Brigitte C Van Der Zanden

John Paul Luzio

Contemplated methods and compositions further increase susceptibility of sensitized MRSA against various antibiotic drugs. Most preferably, the MRSA is already sensitized with a galloylated catechin (e.g., ECG), and further sensitization is achieved by exposure to a non-galloylated catechin (e.g., EC), and most preferably the corresponding non-galloylated catechin.

[object Object]

There is provided a novel compound of the general formula I in which each of Rto Ris hydrogen, aryl, Calkyl, trialkylsilyl or acyl; Rto Rare individually selected from hydrogen, hydroxy, Calkoxy and acyloxy; Rand Rare H, Calkyl, trialkylsilyl or acyl; X is O or NR, and R is H or Me; in which any of the alkyl groups including alkyl groups in alkoxy, acyl and acyloxy groups may be substituted by aryl, Calkyl, Calkoxy, hydroxyl, trialkylsiloxy or acyloxy groups; with the proviso that Rand Rare not both OH when Ris H or OH, Rand Rare both H, and X is O. The amide compounds (X is NR) are analogues of epigallocatechin gallate or epicatechin galate, with an amide bond in place of the natural ester bond, with resistance to hydrolysis by esterase enzymes. The ester compounds (X is O) have a different hydroxylation pattern on the B ring as compared to the natural products. The compounds may be used to modulate the resistance to &#x3b2;-lactam antibiotics of various infections, especially methicillin resistant(MRSA). Pharmaceutical compositions containing the novel compounds and combinations of the novel compounds and &#x3b2;-lactam antibiotics are described.

Compounds for use in the treatment of infection

A recombinant protein having bacteriophage endosialidase enzymatic activity obtainable by expression from a recombinant vector comprising a DNA sequence encoding a bacteriophage endosialidase linked to a DNA sequence of an expression vector which express a polypeptide which adds to the N-terminus of the endosialidase, or an analogue of said protein, which is a mutant, functional fragment or derivative of said protein having endosialidase enzymatic activity.

Recombinant protein having bacteriophage endosialidase enzymatic activity

A topically administrable pharmaceutical composition comprising (A) zinc phthalocyanine complex, (B) as carrier for the complex, (i) a N-alkylpyrrolidone together with a pharmaceutically acceptable co-solvent for the complex, (ii) dimethyl sulphoxide or a mixture thereof with a pharmaceutically acceptable co-solvent for the complex, (iii) a liposome, or (iv) a N,N-dialkylbenzamide or a mixture thereof with a pharmaceutically acceptable co-solvent for the complex, and (C) a gelling agent.

Topically administrable zinc phthalocyanine compositions

Compounds of the general formula: ##STR1## in which R is a lower alkyl group, and R.sub.1 is a tri-lower alkylmethylcarbonyl group, the structure elements --A.sub.1 --A.sub.2 --, A.sub.3 --A.sub.4 -- or A.sub.5 --A.sub.6 -- each represent ethylene or vinylene, or the elements --A.sub.1 --A.sub.2 -- and --A.sub.3 --A.sub.4 -- each represent ethylene and --A.sub.5 --A.sub.6 -- represents vinylene, their optical isomers and their salts exhibit valuable pharmaceutical properties.

Open chain rifamycin derivatives

Growing community of inventors

Billingshurst, United Kingdom

Peter William Taylor